Clinical Trials on Absence Seizures in Italy

Total 75 results

University of Milano Bicocca
Azienda Ospedaliera Universitaria Integrata Verona; Azienda Socio Sanitaria... and other collaborators

Recruiting

Dual Anti-glutamate Therapy in Super-refractory Status Epilepticus After Cardiac Arrest (SUPER-CAT)

Cardiac Arrest | Status Epilepticus

Italy
GlaxoSmithKline

Completed

Long-Term Safety Study of Retigabine Immediate Release (IR) as Adjunctive Therapy in the Treatment of Adults With Partial-Onset Seizures (POS) (IR)

Epilepsy

Bulgaria, Thailand, Russian Federation, Belgium, Italy, Ukraine, France, Germany, Netherlands, Poland
Eisai Inc.

Completed

Evaluation of the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Epilepsy

Belgium, Germany, China, Hong Kong, United States, France, Romania, Mexico, South Africa, India, Portugal, Russian Federation, Italy, Canada, Australia, Taiwan, Austria, Malaysia, Hungary, Poland, Thailand, Sweden, Bulgaria, Serbia, Greece and more
Marinus Pharmaceuticals

Withdrawn

To Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ganaxolone Added to Standard of Care in Refractory Status Epilepticus (RSE)

Refractory Status Epilepticus

Spain, Switzerland, Germany, France, Austria, Italy, Belgium, United Kingdom, Czechia, Croatia, Finland, Lithuania, Israel, Hungary, Poland, Slovakia
Bial - Portela C S.A.

Completed

Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures

Partial Epilepsy

Netherlands, Poland, Italy, Russian Federation, Ukraine
UCB Pharma SA

Completed

Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures

Epilepsy

Belgium, Finland, France, Germany, Hungary, India, Italy, Netherlands, Poland, Spain, Switzerland, United Kingdom
GlaxoSmithKline

Completed

Study of Retigabine Immediate Release as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial-Onset Seizures (IR)

Epilepsy

Bulgaria, Belgium, Thailand, Denmark, Russian Federation, Italy, Spain, Ukraine, Netherlands, Germany, France, Poland
UCB Pharma

Terminated

A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures

Epilepsy

United States, France, Germany, Spain, Hungary, Italy
UCB Pharma

Completed

Study to Investigate Lacosamide as Add-on Therapy in Subjects ≥4 Years to <17 Years of Age With Partial Onset Seizures

Epilepsy

United States, Argentina, Australia, Belgium, Bulgaria, Colombia, Croatia, Czechia, Estonia, Georgia, Hungary, Israel, Italy, Korea, Republic of, Latvia, Lithuania, Mexico, Montenegro, Poland, Romania, Russian Federation, Serbia, Sl... and more
UCB BIOSCIENCES, Inc.
UCB Biopharma SRL

Completed

A Clinical Study to Investigate the Efficacy and Safety of Lacosamide as an Add on Therapy in Children With Epilepsy With Partial-onset Seizures

Epilepsy

United States, Argentina, Australia, Belgium, Brazil, Bulgaria, China, Colombia, Croatia, Czechia, Estonia, France, Georgia, Greece, Hungary, Israel, Italy, Korea, Republic of, Latvia, Lithuania, Mexico, Moldova, Republic of, Monten... and more
UCB Pharma

Completed

Trial to Assess Long-term Lacosamide (LCM) Monotherapy Use and Safety of LCM Monotherapy and Adjunctive Therapy for Partial-onset Seizures

Epilepsy

United States, Australia, Canada, Denmark, Germany, Italy, Poland, United Kingdom, Spain
LivaNova

Active, not recruiting

Registry of Subjects With Drug Resistant Epilepsy and Treated With the VNS Therapy System. (CORE-VNS)

Epilepsy | Seizures | Drug Resistant Epilepsy

Australia, Italy, United States, Israel, United Kingdom, Canada, Brazil, Japan, Belgium, India, Austria, China, Netherlands, Poland, Portugal, Saudi Arabia
UCB Biopharma S.P.R.L.
Pharm Research Associates (UK) Ltd.

Completed

Study to Look at How Effective Briviact is as add-on Treatment for Patients With Epilepsy With Partial Onset Seizures (BASE)

Epilepsy With POS With or Without Secondary Generalization

Denmark, Germany, Hungary, Ireland, Italy, Netherlands, Norway, Spain, United Kingdom
UCB BIOSCIENCES, Inc.

Completed

Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures (ALEX-MT)

Epilepsy

Austria, United States, Australia, Canada, Denmark, France, Germany, Ireland, Italy, Poland, Puerto Rico, Spain, United Kingdom
UCB Pharma

Completed

Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures (BRITE)

Epilepsy

United States, Czechia, Germany, Poland, Austria, Belgium, Brazil, Bulgaria, Canada, Estonia, Finland, France, Hong Kong, Hungary, India, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Mexico, Netherlands, Puerto Rico, Russian Federation and more
Sage Therapeutics

Completed

A Study With SAGE-547 for Super-Refractory Status Epilepticus

Super-Refractory Status Epilepticus

United States, Austria, Canada, Denmark, Estonia, Finland, France, Germany, Hungary, Israel, Italy, Netherlands, Serbia, Spain, Sweden, United Kingdom
UCB Biopharma S.P.R.L.

Terminated

Study to Evaluate the Safety and Efficacy of USL261 (Intranasal Midazolam) in Patients With Seizure Clusters (ARTEMIS1)

Epilepsy

United States, Australia, Canada, Germany, Hungary, Israel, Italy, New Zealand, Poland, Spain, Ukraine
UCB Pharma

Completed

Long-Term, Follow-Up Study Of the Safety And Efficacy Of Levetiracetam In Children With Partial Onset Seizures

Epilepsy, Partial

United States, France, United Kingdom, Germany, Belgium, Mexico, Poland, India, Romania, South Africa, Canada, Brazil, Russian Federation, Czech Republic, Hungary, Italy
UCB Pharma

Completed

A Placebo-controlled Study of Levetiracetam In Children (1mo to 4yrs of Age) With Partial Onset Seizures.

Epilepsy, Partial

United States, France, United Kingdom, Germany, Belgium, Mexico, Poland, Romania, Canada, Brazil, Russian Federation, Argentina, Hungary, Italy, Czechia
UCB Pharma

Completed

Trial to Assess Lacosamide as the First add-on Anti-epileptic Drug Treatment in Patients With Partial-onset Seizures

Partial Epilepsies

United States, Austria, Bulgaria, Czechia, Denmark, Finland, France, Greece, Italy, Mexico, Romania, Russian Federation, Spain, Switzerland, Turkey
Novartis Pharmaceuticals

Completed

A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures (EXIST-3)

Tuberous Sclerosis Complex-associated Refractory Seizures

United States, Colombia, Belgium, France, Japan, Taiwan, Turkey, Spain, Thailand, Korea, Republic of, Australia, Hungary, United Kingdom, Canada, Norway, Germany, Italy, Russian Federation, Denmark, Argentina, Netherlands, Greece, P... and more
SK Life Science, Inc.

Recruiting

Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults

Seizures | Lennox Gastaut Syndrome

United States, Korea, Republic of, Taiwan, Colombia, Australia, Poland, Serbia, Mexico, Spain, Greece, Italy, Portugal, Germany, Argentina, Israel
GRIN Therapeutics, Inc.

Recruiting

A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type II

Tuberous Sclerosis Complex | Focal Cortical Dysplasia

Spain, United Kingdom, Australia, Belgium, Canada, Italy, Poland
Astellas Pharma Global Development, Inc.
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Completed

A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide (UPWARD)

Metastatic Castration-resistant Prostate Cancer (mCRPC)

France, Germany, Spain, United States, Argentina, Australia, Belgium, Canada, Chile, Czechia, Finland, Hungary, Israel, Italy, Korea, Republic of, New Zealand, Singapore, Sweden, Taiwan, United Kingdom
Novartis Pharmaceuticals

Active, not recruiting

Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment

Tuberous Sclerosis Complex

United States, Spain, Belgium, Taiwan, Turkey, Australia, Korea, Republic of, Thailand, France, Hungary, United Kingdom, Italy, Japan, Canada, Russian Federation, Poland, Mexico, Colombia

Clinical Trials on Absence Seizures in Italy

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Korea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations